This report highlights all changes (additions and deletions) to the cvs caremark prescribing guide
Effective 10-01-2012 (Standard Drug List Reflects Exclusions)
This report highlights all changes (additions and deletions) to the CVS Caremark Prescribing Guide. ADDITIONS: Therapeutic Category/ Subcategory Indication Alternatives/Comments Brand Agents: Atelvia
To provide an additional once-weekly treatment option for
osteoporosis that does not need to be administered on an
Brilinta
Hematologic/ Brilinta is indicated to reduce the
To provide an antiplatelet option that is superior to Plavix
(clopidogrel) at reducing cardiovascular events in patients
with ACS and is recommended by the American College
of Cardiology Foundation and the American Heart
Association for use in patients with unstable angina and
To provide an additional NNRTI option with a lower risk of
dyslipidemia and neuropsychiatric adverse events.
This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. 2012 Caremark, L.L.C. All rights reserved. 106-25956c 073012
Effective 10-01-2012 (Standard Drug List Reflects Exclusions) Therapeutic Category/ Subcategory Indication Alternatives/Comments Fluoxetine 60 mg
To provide an additional formulation of fluoxetine that
may be more convenient for patients requiring fluoxetine
Nervosa and Panic Disorder (with or without agoraphobia) in adults.
adolescents aged 8 to 18 years and OCD in children and adolescents aged 7 to 17 years.
Generic Agents: fluvastatin
To provide an additional generic statin option with a low
hypercholesterolemia and mixed dyslipidemia.
irbesartan
To provide an additional generic angiotensin II receptor
blocker (ARB) option with an indication for diabetic kidney
elevated serum creatinine and proteinuria (> 300 mg/day) in patients with type 2 diabetes and hypertension.
This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. 2012 Caremark, L.L.C. All rights reserved. 106-25956c 073012
Effective 10-01-2012 (Standard Drug List Reflects Exclusions) Therapeutic Category/ Subcategory Indication Alternatives/Comments irbesartan/
To provide an additional generic ARB and diuretic
hydrochloro- thiazide
DELETIONS: Therapeutic Category/ Subcategory Indication Alternatives/Comments Brand Agents: Iressa
Iressa (gefitinib) has been withdrawn from the market by
the manufacturer due to lack of efficacy at prolonging
advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies who are benefiting or have benefited from Iressa.
This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. 2012 Caremark, L.L.C. All rights reserved. 106-25956c 073012
Effective 10-01-2012 (Standard Drug List Reflects Exclusions) Therapeutic Category/ Subcategory Indication Alternatives/Comments Metadate CD Central Nervous System/
Availability of other stimulant options for the treatment of
Alternatives on the Prescribing Guide are amphetamine/dextroamphetamine mixed salts extended-release (Adderall XR), dexmethylphenidate (Focalin), dextroamphetamine (Dexedrine), dextroamphetamine extended-release (Dexedrine Spansule), methylphenidate (Methylin), methylphenidate (Ritalin), methylphenidate extended-release (Concerta), methylphenidate extended-release (Ritalin LA), methylphenidate extended-release 10 mg, Daytrana (methylphenidate transdermal), Focalin XR (dexmethylphenidate extended-release), Intuniv (guanfacine extended-release), Strattera (atomoxetine) and Vyvanse (lisdexamfetamine).
Suboxone Film
Availability of other opioid dependence therapy options.
An alternative on the Prescribing Guide is naltrexone
This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. 2012 Caremark, L.L.C. All rights reserved. 106-25956c 073012
The nuclear renaissance – technologies and challenges It is rare that we all seem to agree on any-“double jeopardy” – whereby a plant canthing these days, but one thing few peoplebe built but still not be allowed to operatedisagree with is that global demand for en-– are prohibitive barriers to potential in-ergy in general – and electricity in partic-ular – is set to rise s
PAMIR Conference on Fundamental and Applied MHD Magnetism and magnetic particles in biology MAGNETIC PARTICLES FOR APPLICATION IN BIOMEDICINE M. Timko, M. Konerack´a, N. Tomaˇsoviˇcov´a, P. Kopˇcansk´y, V. Z´aviˇsov´a Institute of Experimental Physics SAS, 47 Watsonova, 043 53 Koˇsice, Slovakia Introduction. Magnetic drug delivery by particulate carriers is a very ef-
Effective 10-01-2012 
Effective 10-01-2012 
Effective 10-01-2012 
Effective 10-01-2012